Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a combination of a bioresorbable nasal stent (Nasopore) and two antibiotics, gentamycin and bacitracin. The Nasopore component is a fragmentable, biodegradable polyurethane foam designed for use as a space-occupying stent in the nasal cavity following surgery or trauma. Its primary functions are to separate mucosal surfaces to prevent adhesions, provide hemostasis by tamponade effect, and absorb blood or drainage. When combined with gentamycin (an aminoglycoside antibiotic) and bacitracin (a polypeptide antibiotic), the device also delivers local antibacterial action to reduce the risk of postoperative infection at the surgical site. Gentamycin acts by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit, while bacitracin interferes with bacterial cell wall synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nasopore Stent + gentamycin + bacitracin.